Insulin Resistance Clinical Trial
Official title:
Comparison Fenofibrate, Rosiglitazone, or Weight Loss to Decrease Cardiovascular Risk in Insulin Resistant Dyslipidemic Individuals.
Approximately 1/4 of the US population has insulin resistance and the associated risk factors such as elevated lipid levels -triglycerides (type of fat from what we eat and what the liver produces and low HDL cholesterol which is the good cholesterol helping to protect against heart disease. Currently one known treatment for this a medication called fenofibrate, another medication that can improve insulin resistance is rosiglitazone, a third treatment known to improve insulin resistance an decrease triglycerides is weight loss. In this study insulin resistant individuals with elevated triglycerides and or a ratio of triglycerides to HDL cholesterol of 3:1 or greater will be randomized (selected by chance) to receive one of these treatments and results of insulin sensitivity and cardiac risk profiles will be compared at the end of the study.
It has been estimated that approximately ¼ of the US population has the Insulin Resistant
Syndrome (IRS). The notion that insulin resistance and compensatory hyperinsulinemia lead to
a cluster of abnormalities that increase CVD risk was first introduced in 1988, and central
to the changes identified was a dyslipidemia characterized by a high plasma triglyceride
(TG) and low high-density lipoprotein cholesterol (HDL-C) concentration. The atherogenic
lipoprotein pattern associated with the IRS has grown to include enhanced postprandial
lipemia and smaller and denser low-density lipoprotein (LDL) particles. In addition to being
associated with insulin resistance and compensatory hyperinsulinemia, these changes in
lipoprotein metabolism have been identified as increasing CVD risk. The power of the
dyslipidemia associated with the IRS is reinforced by reports that the plasma TG/HDL-C
concentration ratio is as powerful a predictor of CVD, if not more so, than the more
conventional total plasma cholesterol/LDL-C concentration ratio, and evidence from the
Copenhagen Male Study of the interaction between the plasma TG and HDL-C concentrations,
“conventional” CVD risk factors, and CVD events. Specifically, these latter investigators
were able to show in a prospective study (11) that CVD events were substantially attenuated
in: 1) smokers; 2) patients with high blood pressure; 3) individuals with a high LDL-C
concentration; and 4) subjects who were sedentary; as long as they were in the lowest 1/3rd
of the population with the lowest TG/HDL-C concentration ratio and presumably insulin
sensitive. Conversely, if they were in the tertile with the highest plasma TG/HDL-C
concentration ratio, and presumably insulin resistant, they had a significant increase in
CVD events in the absence of the four conventional CVD risk factors evaluated.
An obvious alternative therapeutic approach to decreasing CVD risk in patients with the IRS
would be to administer a thiazolidinedione (TZD) compound in an effort to directly treat the
basic defect of the syndrome. However, based upon our own results with rosiglitazone (ROSI)
in several different patient populations, improvements in insulin sensitivity were not
associated with a significant improvement in dyslipidemia. For example, in a recent study
(unpublished) of ROSI-treated patients with type 2 diabetes, neither plasma TG (358 to 347
mg/dL) nor HDL-C (40 to 42 mg/dL) concentrations improved, and both total (215 to 239 mg/dL
and LDL-C (118-142mg/dL) concentrations actually increased. Since the patients in this study
became more insulin sensitive with treatment, and had lower daylong plasma glucose, insulin,
and free fatty acid concentrations, the reason for the lack of a beneficial effect of ROSI
on lipoprotein metabolism is not clear. On the other hand, given evidence of the importance
of dyslipidemia in increasing CVD risk in insulin resistant individuals, it seems reasonable
to question the notion that TZD compounds provide the most beneficial approach to decreasing
CVD risk in the dyslipidemic patient with the IRS.
With this background in mind, we propose to initiate a study in which insulin resistant
individuals with the dyslipidemia characteristic of the IRS will be randomized to treatment
with fenofibrate,ROSI, or weight loss and the effect of these three treatments on CVD risk
factors compared. It is postulated that although insulin resistance will improve to a
greater degree with ROSI treatment, the atherogenic lipoprotein profile known to link IRS
and CVD will only significantly improve following treatment with fenofibrate and effects of
weight loss can effect both of these.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03142633 -
MicroRNA as Biomarkers for Development of Metabolic Syndrome in Women With Polycystic Ovary Syndrome
|
||
Recruiting |
NCT04984226 -
Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD
|
Phase 2 | |
Recruiting |
NCT05354245 -
Using a Complex Carbohydrate Mixture to Steer Fermentation and Improve Metabolism in Adults With Overweight and Prediabetes (DISTAL)
|
N/A | |
Completed |
NCT03383822 -
Regulation of Endogenous Glucose Production by Brain Insulin Action in Insulin Resistance
|
Phase 1/Phase 2 | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Suspended |
NCT03652987 -
Endocrine and Menstrual Disturbances in Women With Polycystic Ovary Syndrome (PCOS)
|
||
Completed |
NCT04203238 -
Potato Research for Enhancing Metabolic Outcomes
|
N/A | |
Recruiting |
NCT03658564 -
Preoperative Oral Carbohydrate Treatment Minimizes Insulin Resistance
|
N/A | |
Completed |
NCT04183257 -
Effect of Escalating Oral Vitamin D Replacement on HOMA-IR in Vitamin D Deficient Type 2 Diabetics
|
Phase 4 | |
Completed |
NCT04117802 -
Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome
|
N/A | |
Completed |
NCT03627104 -
Effect of Dietary Protein and Energy Restriction in the Improvement of Insulin Resistance in Subjects With Obesity
|
N/A | |
Completed |
NCT05124847 -
TREating Pediatric Obesity
|
N/A | |
Active, not recruiting |
NCT03288025 -
Pulmonary Arterial Hypertension Improvement With Nutrition and Exercise (PHINE)
|
N/A | |
Completed |
NCT03809182 -
Effect of Dexmedetomidine on Postoperative Glucose and Insulin Levels.
|
Phase 4 | |
Completed |
NCT01809288 -
Identifying Risk for Diabetes and Heart Disease in Women
|
||
Completed |
NCT04642482 -
Synbiotic Therapy on Intestinal Microbiota and Insulin Resistance in Obesity
|
Phase 4 | |
Terminated |
NCT03278236 -
Does Time Restricted Feeding Improve Glycaemic Control in Overweight Men?
|
N/A | |
Not yet recruiting |
NCT06159543 -
The Effects of Fresh Mango Consumption on Cardiometabolic Outcomes in Free-living Individuals With Prediabetes
|
N/A | |
Withdrawn |
NCT04741204 -
Metformin Use to Reduce Disparities in Newly Diagnosed Breast Cancer
|
Phase 4 | |
Not yet recruiting |
NCT05540249 -
Pre-operative Carbohydrates in Diabetic Patients Undergoing CABG
|
N/A |